<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1186/s13019-019-0993-9</query><apiKey>6b19ee21fe6a243741a528650f7c8997</apiKey><result><total>1</total><start>1</start><pageLength>1</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">13019</journal-id><journal-title-group><journal-title>Journal of Cardiothoracic Surgery</journal-title><abbrev-journal-title abbrev-type="publisher">J Cardiothorac Surg</abbrev-journal-title></journal-title-group><issn pub-type="epub">1749-8090</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s13019-019-0993-9</article-id><article-id pub-id-type="manuscript">993</article-id><article-id pub-id-type="doi">10.1186/s13019-019-0993-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The novel use of oral antibiotic monotherapy in prosthetic valve endocarditis caused by <italic>Finegoldia magna</italic>: a case study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="Au1"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9657-193X</contrib-id><name><surname>Chien</surname><given-names>Siobhan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs1301901909939_cor1">a</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Gorman</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Koutsogiannidis</surname><given-names>Charilaos-Panagiotis</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Ravishankar</surname><given-names>Ramanish</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au5"><name><surname>Kamath</surname><given-names>Ganesh</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au6"><name><surname>Zamvar</surname><given-names>Vipin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0709 1919</institution-id><institution-id institution-id-type="GRID">grid.418716.d</institution-id><institution content-type="org-name">Department of Cardiothoracic Surgery, Royal Infirmary of Edinburgh</institution></institution-wrap><addr-line content-type="street">51 Little France Crescent</addr-line><addr-line content-type="postcode">EH16 4SA</addr-line><addr-line content-type="city">Edinburgh</addr-line><country country="GB">UK</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7988</institution-id><institution-id institution-id-type="GRID">grid.4305.2</institution-id><institution content-type="org-name">University of Edinburgh</institution></institution-wrap><addr-line content-type="city">Edinburgh</addr-line><country country="GB">UK</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1765 924X</institution-id><institution-id institution-id-type="GRID">grid.465547.1</institution-id><institution content-type="org-division">Department of Cardiothoracic Surgery</institution><institution content-type="org-name">Kasturba Medical College</institution></institution-wrap><addr-line content-type="city">Manipal</addr-line><country country="IN">India</country></aff></contrib-group><author-notes><corresp id="IDs1301901909939_cor1"><label>a</label><email>siobhan.chien@nhs.net</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>9</month><year>2019</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2019</year></pub-date><volume>14</volume><issue seq="169">1</issue><elocation-id>170</elocation-id><history><date date-type="registration"><day>10</day><month>9</month><year>2019</year></date><date date-type="received"><day>9</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>10</day><month>9</month><year>2019</year></date><date date-type="online"><day>18</day><month>9</month><year>2019</year></date></history><permissions><copyright-statement>Â© The Author(s). 2019</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="url">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" ext-link-type="url">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1" xml:lang="en"><title>Abstract</title><sec id="ASec1"><title>Background</title><p id="Par1"><italic>Finegoldia magna</italic>, a Gram-positive anaerobic coccus, is part of the human normal microbiota as a commensal of mucocutaneous surfaces. However, it remains an uncommon pathogen in infective endocarditis, with only eight clinical cases previously reported in the literature.</p><p id="Par2">Currently, infective endocarditis is routinely treated with prolonged intravenous antibiotic therapy. However, recent research has found that switching patients to oral antibiotics is non-inferior to prolonged parenteral antibiotic treatment, challenging the current guidelines for the treatment of infective endocarditis.</p></sec><sec id="ASec2"><title>Case presentation</title><p id="Par3">This case report focuses on a 52-year-old gentleman, who presented with initially culture-negative infective endocarditis following bioprosthetic aortic valve replacement. Blood cultures later grew <italic>Finegoldia magna</italic>. Following initial intravenous antibiotic therapy and re-do surgical replacement of the prosthetic aortic valve, the patient was successfully switched to oral antibiotic monotherapy, an unusual strategy in the treatment of infective endocarditis inspired by the recent publication of the POET trial. He made excellent progress on an eight-week course of oral antibiotics and was successfully discharged from surgical follow-up.</p></sec><sec id="ASec3"><title>Conclusions</title><p id="Par4">This case is the 9th reported case of <italic>Finegoldia magna</italic> infective endocarditis in the literature. Our case also raises the possibility of a more patient-friendly and cost-effective means of providing long-term antibiotic therapy in suitable patients with prosthetic valve endocarditis and suggests that the principles highlighted in the POET trial can also be applicable to post-operative patients after cardiac surgery.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>Finegoldia magna</italic></kwd><kwd>Prosthetic valve endocarditis</kwd><kwd>Oral antibiotics</kwd><kwd>Administration</kwd><kwd>Cardiac surgical procedures</kwd><kwd>Treatment outcome</kwd><kwd>Infective endocarditis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>BioMed Central</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>2</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>No</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>9</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>10</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/13019_2019_Article_993.pdf</meta-value></custom-meta><custom-meta><meta-name>pdf-type</meta-name><meta-value>Typeset</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Medicine &amp; Public Health</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Cardiac Surgery</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Thoracic Surgery</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Medicine</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par15"><italic>Finegoldia magna</italic> (previously known as <italic>Peptostreptococcus magnus</italic>) is the most commonly isolated Gram-positive anaerobic cocci (GPAC) from clinical specimens, and is a normal commensal of human mucocutaneous surfaces [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. However, it remains a rare and unusual microbe implicated in the pathogenesis of infective endocarditis.</p><p id="Par16">Although relatively rare, infective endocarditis carries a substantial morbidity and mortality risk, with current guidelines advocating the administration of prolonged, parenteral bactericidal therapy for complete infection eradication [<xref ref-type="bibr" rid="CR3">3</xref>]. The recent publication of the Partial Oral Treatment of Endocarditis (POET) trial has recently proven switching patients with infective endocarditis to oral antibiotic therapy to be non-inferior to continued intravenous (IV) antibiotic therapy [<xref ref-type="bibr" rid="CR4">4</xref>], challenging whether prolonged administration of parenteral antibiotics is necessary in a specific subset of patients with infective endocarditis.</p></sec><sec id="Sec2"><title>Case report</title><p id="Par17">A 52-year-old man presented to our Emergency Department with sweats, lethargy and weakness 5âweeks following tissue aortic valve replacement with a 23âmm bioprosthetic valve. His background included severe aortic stenosis, mild left ventricular impairment, atrial fibrillation, hyperthyroidism, obstructive sleep apnoea and autistic spectrum disorder.</p><p id="Par18">Following the original aortic valve replacement, the patient had made a good recovery, although he had been noted to be sweating at times. He maintained a normal white cell count and was apyrexial throughout, and was discharged home on postoperative day 6. Immediately following discharge, he did reattend via the Emergency Department with sweats and back pain, and was diagnosed with a lower respiratory tract infection.</p><p id="Par19">Having re-presented with generalised weakness, lethargy and sweats, clinical examination was unremarkable and bloods demonstrated only a raised C-reactive protein (CRP) of 48. Trans-thoracic echocardiography demonstrated no evidence of endocarditis. Blood cultures taken on admission were initially reported as negative. However, during his admission the patient became pyrexial with worsening sweats and rigors. Urine culture, viral throat swab, CT scanning and dental review revealed no clear source of infection. There was no suggestion of immunocompromise or other risk factors for infection with this unusual pathogen.</p><p id="Par20">Trans-oesophageal echocardiography on day 6 revealed infective endocarditis of the prosthetic aortic valve (see Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). Antibiotic cover was broadened to IV vancomycin, IV gentamicin and oral metronidazole. Pyrexia and inflammatory markers improved following this. IV gentamicin was later stopped on microbiology advice. Four days following admission, one set of blood cultures grew a Gram-positive anaerobe coccus, later identified as <italic>Finegoldia magna</italic> on day ten. Antibiotic sensitivities were assessed using gradient strip diffusion and are shown in Table <xref rid="Tab1" ref-type="table">1</xref>.
<fig id="Fig1"><label>Fig. 1</label><caption xml:lang="en"><p>Trans-oesophageal echocardiography (TOE) showing (<bold>a</bold>) location and size of vegetation and (<bold>b</bold>) mitral regurgitation</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/13019_2019_993_Fig1_HTML.png" id="MO1"/></p></fig><table-wrap id="Tab1"><label>Table 1</label><caption xml:lang="en"><p>Antibiotic sensitivities of cultured <italic>F. magna</italic>. A lower MIC value indicates greater sensitivity to the tested antibiotic</p></caption><table frame="hsides" rules="groups"><thead><tr><th><p>Antibiotic tested</p></th><th><p>Minimum inhibitory concentration (MIC)</p></th></tr></thead><tbody><tr><td><p>Clindamycin</p></td><td><p>0.064âmg/L</p></td></tr><tr><td><p>Co-amoxiclav</p></td><td><p>0.500âmg/L</p></td></tr><tr><td><p>Metronidazole</p></td><td><p>0.047âmg/L</p></td></tr><tr><td><p>Penicillin</p></td><td><p>0.064âmg/L</p></td></tr><tr><td><p>Vancomycin</p></td><td><p>0.094âmg/L</p></td></tr></tbody></table></table-wrap></p><p id="Par21">Intravenous antibiotic therapy was commenced. The decision was taken to resort to surgical intervention with replacement of the infected prosthetic valve. The patient underwent re-do surgery with removel of the infected valve and implantation of another bioprosthetic valve. Culture and sensitivities from the excised valve were negative.</p><p id="Par22">After 19âdays of IV vancomycin and oral metronidazole, vancomycin was stopped. Given the excellent oral bioavailability of metronidazole, the decision was taken to treat the anaerobic infective endocarditis with oral metronidazole monotherapy. The patientâs improving clinical condition, improving inflammatory markers and the achievement of source control through surgery supported the decision to switch to oral therapy.</p><p id="Par23">The patient progressed well and was discharged on post-operative day 13 to complete a total 8-week course of oral metronidazole from the date of re-do surgery. Regular monitoring of CRP confirmed continuing improvement. He was discharged from follow-up eight weeks later, with final âtest of cureâ blood cultures reported as negative. No adverse effects following re-operation and prolonged antibiotic treatment were reported.</p></sec><sec id="Sec3" sec-type="discussion"><title>Discussion</title><p id="Par24"><italic>Finegoldia magna,</italic> previously known as <italic>Peptostreptococcus magnus</italic> [<xref ref-type="bibr" rid="CR5">5</xref>], is a Gram-positive anaerobic coccus (GPAC), and like other GPACs is a common commensal of human skin, mucous membranes, and gastrointestinal and genitourinary tracts [<xref ref-type="bibr" rid="CR6">6</xref>â<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par25">Of the GPACs, <italic>F. magna</italic> is thought to be amongst the most pathogenic, and is a common isolate from skin and soft tissue infections, bone and joint infections, and diabetic foot infections [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Its particular virulence is thought to be the product of a number of adaptations. Well described are: the expression of pili, which assist in adhesion and colonisation; the ability to bind to human albumin by way of a peptostreptococcal albumin-binding protein leading to accelerated growth rates; and expression of superantigens targeting B cells (the most common being Protein L) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par26">Whilst the infections above due to <italic>F. magna</italic> appear to be relatively common, confirmed infective endocarditis due to <italic>F. magna</italic> is notably more rare. A search of the English-language literature reveals eight previously reported cases of endocarditis with <italic>F. magna</italic> or <italic>P. magnus</italic> as the confirmed causative organism.</p><p id="Par27">Of note, blood cultures were negative in the majority of <italic>F. magna</italic> infective endocarditis cases, with definitive diagnosis made only by tissue specimens obtained during surgery [<xref ref-type="bibr" rid="CR13">13</xref>]. Blood cultures yielded a positive microbiology result after four days in our case. Culture-negative infective endocarditis has a potentially negative impact on patient management, as this can lead to delays in the diagnosis and the initiation of the appropriate antibiotic regimen according to sensitivities [<xref ref-type="bibr" rid="CR14">14</xref>]. Therefore, it is important to consider <italic>F. magna</italic> infection in a patient presenting with clinical suspicion of infective endocarditis after cardiac valvular surgery with initially sterile blood cultures [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p id="Par28">According to guidelines from the European Society of Cardiology (ESC) and the American Heart Association (AHA), management of infective endocarditis classically involves the administration of intravenous antibiotics for up to 6âweeksâ duration [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. The majority of complications, including in-hospital mortality, are found to occur within the initial phase after admission [<xref ref-type="bibr" rid="CR16">16</xref>â<xref ref-type="bibr" rid="CR18">18</xref>]. A significant number of clinically stable patients are therefore subjected to a prolonged hospital admission after this initial phase to facilitate the administration of intravenous antibiotic therapy. Prolonged hospital stay is associated with an increased physical and psychological burden [<xref ref-type="bibr" rid="CR19">19</xref>â<xref ref-type="bibr" rid="CR22">22</xref>], whereas shorter inpatient admissions have better outcomes in other diseases and are more cost-effective [<xref ref-type="bibr" rid="CR23">23</xref>â<xref ref-type="bibr" rid="CR25">25</xref>]. The European and American guidelines consequently recommend the use of outpatient parenteral treatment in patients fulfilling certain criteria to alleviate the risks and complications associated with longer duration of hospital stay [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>].</p><p id="Par29">However, the use of outpatient parenteral treatment is not without its challenges. For example, logistical issues must be addressed, patient and staff education is fundamental, close monitoring is required for efficacy and adverse effects, and patients must receive easy access to medical advice, in addition to adequate social and psychological support [<xref ref-type="bibr" rid="CR4">4</xref>]. It has previously been hypothesised that the use of oral antibiotic therapy for the latter stages of the treatment period in stable patients with infective endocarditis would pose an appropriate alternative solution to these challenges, by allowing treatment to take place outside hospitals and without the need for intravenous catheters. However, this approach has been restricted due to the limited clinical evidence base for the safety and efficacy of oral antibiotic therapy for infective endocarditis [<xref ref-type="bibr" rid="CR28">28</xref>â<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par30">The POET trial was published in the New England Journal of Medicine in 2018. 400 clinically stable patients with infective endocarditis on the left side of the heart were involved in this randomised unblinded trial, and were assigned to either continue intravenous treatment or to switch to oral antibiotic treatment, after the administration of at least 10âdays of intravenous antibiotics. At the time of randomisation, at least 10âdays of scheduled antibiotic treatment had to remain. The patients in the orally treated group were then discharged to outpatient treatment, if feasible. The POET trial confirmed that, in clinically stable patients with endocarditis on the left side of the heart, changing to oral antibiotic therapy was non-inferior to continued intravenous antibiotic therapy [<xref ref-type="bibr" rid="CR4">4</xref>]. This supports the treatment of this patient with prolonged duration oral antibiotic therapy.</p><p id="Par31">Previously, it had been suggested that intravenous antibiotic therapy was superior to the use of oral agents for infective endocarditis, with the main concern suggestive that gastric absorption of oral agents may be inadequate to allow sufficient plasma concentrations of antibiotics to facilitate bacterial killing [<xref ref-type="bibr" rid="CR24">24</xref>]. The POET trial emphasises the importance of normal gastrointestinal function to facilitate the uptake of orally administered antibiotics [<xref ref-type="bibr" rid="CR4">4</xref>]. The patient was commenced on IV vancomycin and oral metronidazole originally based on sensitivity results. Vancomycin must be administered via the intravenous route to adequately treat most infections, due to its poor oral bioavailability (&lt;â10%) [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par32">There is other evidence to support the choice of oral metronidazole monotherapy: oral metronidazole is known to have a high bioavailability (98.9%) [<xref ref-type="bibr" rid="CR34">34</xref>], with similar peak serum concentrations when administered via either the oral or intravenous route [<xref ref-type="bibr" rid="CR35">35</xref>]. Oral metronidazole tablets are therefore often the preferred mode of administration, if tolerated. In this case, metronidazole was found to have a minimum inhibitory concentration of 0.047âmg/L, approximately 1/85th of the breakpoint concentration at which an organism is deemed metronidazole-sensitive, as per EUCAST guidelines current at the time of treatment [<xref ref-type="bibr" rid="CR36">36</xref>]. This gave a good degree of confidence that metronidazole monotherapy would provide sufficient antimicrobial therapy.</p><p id="Par33">Although clindamycin was indicated as another possible therapy by sensitivity testing, it is not usual practice in the UK to use clindamycin in the treatment of any bacterial endocarditis [<xref ref-type="bibr" rid="CR37">37</xref>]. Furthermore, it was felt that a prolonged course of clindamycin was potentially harmful due to the significant associated risk of <italic>Clostridium difficile</italic> infection [<xref ref-type="bibr" rid="CR38">38</xref>]. This supported the decision to treat with oral metronidazole alone.</p><p id="Par34">In contrast to our case, the POET trial includes patients with endocarditis on the left side of the heart caused by <italic>Streptococcus</italic>, <italic>Enterococcus faecalis</italic>, <italic>Staphylococcus aureus</italic>, or coagulase-negative <italic>Staphylococci</italic> [<xref ref-type="bibr" rid="CR4">4</xref>]. In the case of this patient, blood cultures were positive for <italic>F. magna</italic>, an anaerobic organism. Infective endocarditis caused by anaerobic pathogens remains relatively uncommon, and accounts for only 2â16% of all cases of infective endocarditis over the past four decades [<xref ref-type="bibr" rid="CR39">39</xref>â<xref ref-type="bibr" rid="CR42">42</xref>]. The POET trial did not include patients in whom an anaerobic pathogen was the causative organism. This case has demonstrated that switching to oral antibiotic therapy in a patient with an anaerobic infective endocarditis could also be satisfactory, but further research is required to prove if this statement could be substantiated with clinical evidence.</p><p id="Par35">In addition, when switching to the oral route in the POET trial, all oral regimens included two antibiotics from different drug classes and with different antibacterial effects and different metabolization processes. This was to reduce the risk of pharmacokinetic variations of the orally administered antibiotics [<xref ref-type="bibr" rid="CR43">43</xref>]. We have differed in offering only metronidazole as monotherapy, for the reasons outlined above and with a good degree of confidence that it would provide suitable cover. The POET trial has demonstrated that oral therapy with two agents was sufficient in the treatment of aerobic endocarditis in selected cases [<xref ref-type="bibr" rid="CR4">4</xref>]. We have added to this evidence a case in which an anaerobic endocarditis was found to be treatable with oral monotherapy alone. In a time of renewed focus on antibiotic stewardship and avoidance of unnecessary use of antimicrobials, this is an exciting development.</p><p id="Par36">Our patient received a total of 62âdays of oral metronidazole, with only 6âdays of IV metronidazole given during the immediate post-operative period in the intensive care setting, compared to only 19âdays of IV vancomycin. Follow-up demonstrated clinical and biochemical evidence of cure. This suggests that the use of single agent oral antibiotic regimens may be a possible development in the future of infective endocarditis treatment. However, further research is required to determine the safety and efficacy of oral antibiotic monotherapy in the future.</p></sec><sec id="Sec4" sec-type="conclusions"><title>Conclusion</title><p id="Par37">We have discussed an unusual case of <italic>F. magna</italic> endocarditis affecting a bioprosthetic heart valve. Because of the tendency toward negative blood cultures in the early stages of diagnosis, a high index of suspicion is needed to diagnose endocarditis in vulnerable patients with non-specific features. This case also demonstrates successful treatment of an anaerobic endocarditis with outpatient oral antibiotic therapy. This builds on previous work which has shown outpatient oral antibiotics to be a feasible treatment for selected cases. Further research in this area may lead to practice changes that significantly reduce length of hospital stay, and its associated risks and costs, in these patients.</p></sec></body><back><ack><title>Acknowledgements</title><p>We thank the patient for allowing us to present and analyse his clinical experience in this case report, and thank the staff within the Cardiothoracic Department at the Royal Infirmary of Edinburgh for their support in writing this case report. In particular, we wish to acknowledge Dr. Ewan Olson for sharing his expertise and knowledge in the area of cardiac microbiology.</p></ack><sec sec-type="author-contribution"><title>Authorsâ contributions</title><p>S Chien and D Gorman conceived of the presented idea, analysed the relevant literature and wrote the manuscript. CP Koutsogiannidis and V Zamvar provided critical feedback and supervised the findings. All authors read and approved the final manuscript.</p></sec><sec><title>Funding</title><p>Not applicable.</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.</p></sec><sec sec-type="ethics-statement"><sec id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par38">Not applicable.</p></sec><sec id="FPar2"><title>Consent for publication</title><p id="Par39">Written informed consent was obtained from the patient for publication of this case report.</p></sec><sec id="FPar3" sec-type="COI-statement"><title>Competing interests</title><p id="Par40">The authors declare that they have no competing interests.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>DA</given-names></name></person-group><article-title xml:lang="en">Gram-positive anaerobic cocci</article-title><source>Clin Microbiol Rev</source><year>1998</year><volume>11</volume><fpage>81</fpage><lpage>120</lpage><pub-id pub-id-type="coi">1:STN:280:DyaK1c7hvVOmtA%3D%3D</pub-id><pub-id pub-id-type="doi">10.1128/CMR.11.1.81</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pouedras</surname><given-names>P</given-names></name><name><surname>Donnio</surname><given-names>PY</given-names></name><name><surname>Sire</surname><given-names>JM</given-names></name><etal/></person-group><article-title xml:lang="en">Prosthetic valve endocarditis and paravalvular abscess caused by Peptostreptococcus magnus</article-title><source>Clin Infect Dis</source><year>1992</year><volume>15</volume><fpage>185</fpage><pub-id pub-id-type="coi">1:STN:280:DyaK38zhsVanuw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1093/clinids/15.1.185</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baddour</surname><given-names>LM</given-names></name><name><surname>Wilson</surname><given-names>WR</given-names></name><name><surname>Bayer</surname><given-names>AS</given-names></name><etal/></person-group><article-title xml:lang="en">Infective endocarditis in adults: diagnosis, antimicrobial therapy, and Management of Complications. A scientific statement for professionals from the American Heart Association</article-title><source>Circulation</source><year>2015</year><volume>132</volume><issue>15</issue><fpage>1435</fpage><lpage>1486</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXhs1Krs7fM</pub-id><pub-id pub-id-type="doi">10.1161/CIR.0000000000000296</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iversen</surname><given-names>K</given-names></name><name><surname>Ihlemann</surname><given-names>N</given-names></name><name><surname>Gill</surname><given-names>SU</given-names></name><etal/></person-group><article-title xml:lang="en">Partial Oral versus intravenous antibiotic treatment of endocarditis</article-title><source>N Engl J Med</source><year>2019</year><volume>380</volume><fpage>415</fpage><lpage>424</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1MXis1Onu7c%3D</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa1808312</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenthal</surname><given-names>ME</given-names></name><name><surname>Rojtman</surname><given-names>AD</given-names></name><name><surname>Frank</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">Finegoldia magna (formerly Peptostreptococcus magnus): an overlooked etiology for toxic shock syndrome?</article-title><source>Med Hypotheses</source><year>2012</year><volume>79</volume><issue>2</issue><fpage>138</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2012.04.013</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finegold</surname><given-names>SM</given-names></name></person-group><article-title xml:lang="en">Anaerobic infections in humans: an overview</article-title><source>Anaerobe</source><year>1995</year><volume>1</volume><issue>1</issue><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BD28vmtlyhsg%3D%3D</pub-id><pub-id pub-id-type="doi">10.1016/S1075-9964(95)80340-8</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>A</given-names></name><name><surname>Hirakawa</surname><given-names>H</given-names></name><etal/></person-group><article-title xml:lang="en">Complete genome sequence of Finegoldia magna, an anaerobic opportunistic pathogen</article-title><source>DNA Res</source><year>2008</year><volume>15</volume><issue>1</issue><fpage>39</fpage><lpage>47</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD1cXjvFemsbg%3D</pub-id><pub-id pub-id-type="doi">10.1093/dnares/dsm030</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>OâBrien</surname><given-names>MT</given-names></name><etal/></person-group><article-title xml:lang="en">A case of <italic>Finegoldia magna</italic> (formerly <italic>Peptostreptococcus magnus</italic>) infection mimicking disseminated malignancy</article-title><source>Int J Infect Dis</source><year>2016</year><volume>53</volume><fpage>12</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2016.10.006</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jneid</surname><given-names>J</given-names></name><name><surname>Cassir</surname><given-names>N</given-names></name><name><surname>Schuldiner</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Exploring the microbiota of diabetic foot infections with culturomics</article-title><source>Front Cell Infect Microbiol</source><year>2018</year><volume>8</volume><fpage>282</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2018.00282</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>SÃ¶derquist</surname><given-names>B</given-names></name><name><surname>BjÃ¶rklund</surname><given-names>S</given-names></name><name><surname>Hellmark</surname><given-names>B</given-names></name><etal/></person-group><article-title xml:lang="en"><italic>Finegoldia magna</italic> isolated from orthopaedic joint associated infections</article-title><source>J Clin Microbiol</source><year>2017</year><volume>55</volume><issue>11</issue><fpage>3283</fpage><lpage>3291</lpage><pub-id pub-id-type="doi">10.1128/JCM.00866-17</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>BrÃ¼ggemann</surname><given-names>H</given-names></name><name><surname>Jensen</surname><given-names>A</given-names></name><name><surname>Nazipi</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Pan-genome analysis of the genus <italic>Finegoldia</italic> identifies two distinct clades, strain-specific heterogeneity, and putative virulence factors</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><fpage>266</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-18661-8</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyanova</surname><given-names>L</given-names></name><name><surname>Markovska</surname><given-names>R</given-names></name><name><surname>Miltov</surname><given-names>I</given-names></name></person-group><article-title xml:lang="en">Virulence arsenal of the most pathogenic species among the gram-positive anaerobic cocci, Finegoldia magna</article-title><source>Anaerobe.</source><year>2016</year><volume>42</volume><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.anaerobe.2016.10.007</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hussein</surname><given-names>K</given-names></name><name><surname>Savin</surname><given-names>Z</given-names></name><name><surname>Shani</surname><given-names>L</given-names></name><etal/></person-group><article-title xml:lang="en">Infective endocarditis caused by <italic>Finegoldia magna</italic> following aortic dissection repair: a case report and data evaluation</article-title><source>Am J Case Rep</source><year>2014</year><volume>15</volume><fpage>554</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.12659/AJCR.892057</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siciliano</surname><given-names>RF</given-names></name><name><surname>Mansur</surname><given-names>AJ</given-names></name><name><surname>Castelli</surname><given-names>JB</given-names></name><etal/></person-group><article-title xml:lang="en">Community-acquired culture-negative endocarditis: clinical characteristics and risk factors for mortality</article-title><source>Int J Infect Dis</source><year>2014</year><volume>25</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2014.05.005</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>G</given-names></name><name><surname>Lancellotti</surname><given-names>P</given-names></name><name><surname>Antunes</surname><given-names>MJ</given-names></name><etal/></person-group><article-title xml:lang="en">2015 ESC guidelines for the management of infective endocarditis: the task force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><issue>44</issue><fpage>3075</fpage><lpage>3128</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv319</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickerman</surname><given-names>SA</given-names></name><name><surname>Abrutyn</surname><given-names>E</given-names></name><name><surname>Barsic</surname><given-names>B</given-names></name><etal/></person-group><article-title xml:lang="en">The relationship between the iniaition of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE prospective cohort study (ICE-PCS)</article-title><source>Am Heart J</source><year>2007</year><volume>154</volume><fpage>1086</fpage><lpage>1094</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2sXhtlCrsb%2FI</pub-id><pub-id pub-id-type="doi">10.1016/j.ahj.2007.07.023</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MartÃ­n-DÃ¡vila</surname><given-names>P</given-names></name><name><surname>Navas</surname><given-names>E</given-names></name><name><surname>FortÃºn</surname><given-names>J</given-names></name><etal/></person-group><article-title xml:lang="en">Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size</article-title><source>Am Heart J</source><year>2005</year><volume>150</volume><fpage>1099</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2005.02.009</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdoch</surname><given-names>DR</given-names></name><name><surname>Corey</surname><given-names>GR</given-names></name><name><surname>Hoen</surname><given-names>B</given-names></name><etal/></person-group><article-title xml:lang="en">Clinical presentation, etiology, and outcome of infective endocarditis in the 21<sup>st</sup> century: the international collaboration on endocarditis â prospective cohort study</article-title><source>Arch Intern Med</source><year>2009</year><volume>169</volume><fpage>463</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1001/archinternmed.2008.603</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>SK</given-names></name><name><surname>Preisler</surname><given-names>P</given-names></name><name><surname>Pedersen</surname><given-names>BD</given-names></name></person-group><article-title xml:lang="en">Patients perspective on endocarditis â an intermezzo in life</article-title><source>Eur J Cardiovasc Nurs</source><year>2010</year><volume>9</volume><fpage>126</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.ejcnurse.2009.11.007</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verhagen</surname><given-names>DW</given-names></name><name><surname>Hermanides</surname><given-names>J</given-names></name><name><surname>Korevaar</surname><given-names>JC</given-names></name><etal/></person-group><article-title xml:lang="en">Health-related quality of life and posttraumatic stress disorder among survivors of left-sided native valve endocarditis</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><fpage>1559</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1086/598930</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Saint-Hubert</surname><given-names>M</given-names></name><name><surname>Schoevaerdts</surname><given-names>D</given-names></name><name><surname>Poulain</surname><given-names>G</given-names></name><etal/></person-group><article-title xml:lang="en">Risk factors predicting later functional decline in older hospitalised patients</article-title><source>Acta Clin Belg</source><year>2009</year><volume>64</volume><fpage>187</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1179/acb.2009.034</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaia</surname><given-names>G</given-names></name><name><surname>Maero</surname><given-names>B</given-names></name><name><surname>Gatti</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">Risk factors of functional decline during hospitalization in the oldest old</article-title><source>Aging Clin Exp Res</source><year>2009</year><volume>21</volume><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1007/BF03327448</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehlet</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Fast-track colorectal surgery</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>791</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60357-8</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khoo</surname><given-names>CK</given-names></name><name><surname>Vickery</surname><given-names>CJ</given-names></name><name><surname>Forsyth</surname><given-names>N</given-names></name><etal/></person-group><article-title xml:lang="en">A prospective randomized controlled trial of multimodal perioperative management protocol in patients undergoing elective colorectal resection for cancer</article-title><source>Ann Surg</source><year>2007</year><volume>245</volume><fpage>867</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000259219.08209.36</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wind</surname><given-names>J</given-names></name><name><surname>Polle</surname><given-names>SW</given-names></name><name><surname>Fung Kon Kin</surname><given-names>PH</given-names></name><etal/></person-group><article-title xml:lang="en">Systematic review of enhanced recovery programmes in colonic surgery</article-title><source>Br J Surg</source><year>2006</year><volume>93</volume><fpage>800</fpage><lpage>809</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BD28znsVKhsw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1002/bjs.5384</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>MM</given-names></name><name><surname>von Reyn</surname><given-names>CF</given-names></name></person-group><article-title xml:lang="en">Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis</article-title><source>Clin Infect Dis</source><year>2001</year><volume>33</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BD3MzlslGisg%3D%3D</pub-id><pub-id pub-id-type="doi">10.1086/321814</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>A</given-names></name><name><surname>Revest</surname><given-names>M</given-names></name><name><surname>Patrat-Delon</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Outpatient parenteral antimicrobial therapy for infective endocarditis: a cost-effective strategy</article-title><source>Med Mal Infect</source><year>2014</year><volume>44</volume><fpage>327</fpage><lpage>330</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BC2cbitVemtg%3D%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.medmal.2014.05.001</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Omari</surname><given-names>A</given-names></name><name><surname>Cameron</surname><given-names>DW</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><etal/></person-group><article-title xml:lang="en">Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review</article-title><source>BMC Infect Dis</source><year>2014</year><volume>14</volume><fpage>140</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-14-140</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heldman</surname><given-names>AW</given-names></name><name><surname>Hartert</surname><given-names>TV</given-names></name><name><surname>Ray</surname><given-names>SC</given-names></name><etal/></person-group><article-title xml:lang="en">Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy</article-title><source>Am J Med</source><year>1996</year><volume>101</volume><fpage>68</fpage><lpage>76</lpage><pub-id pub-id-type="coi">1:CAS:528:DyaK28XltVaisrY%3D</pub-id><pub-id pub-id-type="doi">10.1016/S0002-9343(96)00070-8</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dworkin</surname><given-names>RJ</given-names></name><name><surname>Lee</surname><given-names>BL</given-names></name><name><surname>Sande</surname><given-names>MA</given-names></name><name><surname>Chambers</surname><given-names>HF</given-names></name></person-group><article-title xml:lang="en">Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin</article-title><source>Lancet.</source><year>1989</year><volume>2</volume><fpage>1071</fpage><lpage>1073</lpage><pub-id pub-id-type="coi">1:STN:280:DyaK3c%2Fkt1Oltw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(89)91083-0</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iversen</surname><given-names>K</given-names></name><name><surname>HÃ¸st</surname><given-names>N</given-names></name><name><surname>Bruun</surname><given-names>NE</given-names></name><etal/></person-group><article-title xml:lang="en">Partial oral treatment of endocarditis</article-title><source>Am Heart J</source><year>2013</year><volume>165</volume><fpage>116</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2012.11.006</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mzabi</surname><given-names>A</given-names></name><name><surname>KernÃ©is</surname><given-names>S</given-names></name><name><surname>Richaud</surname><given-names>C</given-names></name><name><surname>Podglajen</surname><given-names>I</given-names></name><name><surname>Fernandez-Gerlinger</surname><given-names>MP</given-names></name><name><surname>Mainardi</surname><given-names>JL</given-names></name></person-group><article-title xml:lang="en">Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non-severely ill patients</article-title><source>Clin Microbiol Infect</source><year>2016</year><volume>22</volume><fpage>607</fpage><lpage>612</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BC28bhtFWrtw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.cmi.2016.04.003</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler-Laporte</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">De LâÃtoile-Morel S, Cheng MP, McDonald EG, Lee TC. MRSA colonization status as a predictor of clinical infection: a systematic review and meta-analysis</article-title><source>J Inf Secur</source><year>2018</year><volume>77</volume><issue>6</issue><fpage>489</fpage><lpage>495</lpage></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>LL</given-names></name><name><surname>Rowland</surname><given-names>J</given-names></name><name><surname>Ling</surname><given-names>CHY</given-names></name><name><surname>Fiakos</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">A quantity survey of intravenous administration of metronidazole in its different forms in a tertiary teaching hospital</article-title><source>Intern Med J</source><year>2010</year><volume>40</volume><issue>8</issue><fpage>592</fpage><lpage>596</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BC3cjlvVGjtw%3D%3D</pub-id><pub-id pub-id-type="doi">10.1111/j.1445-5994.2010.02267.x</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralph</surname><given-names>ED</given-names></name></person-group><article-title xml:lang="en">Clinical pharmacokinetics of metronidazole</article-title><source>Clin Pharmacokinet</source><year>1983</year><volume>8</volume><issue>1</issue><fpage>43</fpage><lpage>62</lpage><pub-id pub-id-type="coi">1:STN:280:DyaL3s7otFWisA%3D%3D</pub-id><pub-id pub-id-type="doi">10.2165/00003088-198308010-00003</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">The European committee on antimicrobial susceptibility testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 8.1. 2018. Available from: <ext-link xlink:href="http://www.eucast.org" ext-link-type="url">www.eucast.org</ext-link>.</mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>TS</given-names></name><name><surname>Foweraker</surname><given-names>J</given-names></name><name><surname>Gould</surname><given-names>FK</given-names></name><name><surname>Perry</surname><given-names>JD</given-names></name><name><surname>Sandoe</surname><given-names>JA</given-names></name></person-group><article-title xml:lang="en">Working Party of the British Society for antimicrobial chemotherapy. Guidelines for the antibiotic treatment of endocarditis in adults: report of the working Party of the British Society for antimicrobial chemotherapy</article-title><source>J Antimicrob Chemother</source><year>2004</year><volume>54</volume><issue>6</issue><fpage>971</fpage><lpage>981</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2cXhtVOjsrjJ</pub-id><pub-id pub-id-type="doi">10.1093/jac/dkh474</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Pan J, Kavanagh K, Marwick C, et al. Residual effect of community antimicrobial exposure on risk of hospital onset healthcare associated Clostridioides difficile infection: a case-control study using national linked data. J Hosp Infect 2019 Jun 4. doi: <ext-link xlink:href="https://doi.org/10.1016/j.jhin.2019.05.016" ext-link-type="doi">https://doi.org/10.1016/j.jhin.2019.05.016</ext-link>. [Epub ahead of print].</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feiner</surname><given-names>JM</given-names></name><name><surname>Dowell</surname><given-names>VR</given-names><suffix>Jr</suffix></name></person-group><article-title xml:lang="en">Anaerobic bacterial endocarditis</article-title><source>N Engl J Med</source><year>1970</year><volume>283</volume><fpage>1188</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1056/NEJM197011262832203</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapico</surname><given-names>FL</given-names></name><name><surname>Sarma</surname><given-names>RJ</given-names></name></person-group><article-title xml:lang="en">Infective endocarditis due to anaerobic and microaerophilic bacteria</article-title><source>West J Med</source><year>1982</year><volume>137</volume><issue>1</issue><fpage>18</fpage><lpage>23</lpage><pub-id pub-id-type="coi">1:STN:280:DyaL3s%2Fktlajuw%3D%3D</pub-id><pub-id pub-id-type="pmid">7135941</pub-id><pub-id pub-id-type="pmcid">1273978</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Reyn</surname><given-names>CF</given-names></name><name><surname>Levy</surname><given-names>BS</given-names></name><name><surname>Arbelt</surname><given-names>RD</given-names></name><etal/></person-group><article-title xml:lang="en">Infective endocarditis: an analysis based on strict case definitions</article-title><source>Ann Intern Med</source><year>1981</year><volume>94</volume><fpage>505</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-94-4-505</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Wilson WR, Geraci JE. Anaerobic infections of the cardiovascular system. First United States metronidazole conference. Eds Finegold SM et al. Biomedical information information Corp. NY. 319-330. Proceedings from a symposium, Tarpon Springs, Florida, February 19â20, 1982.</mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassetti</surname><given-names>S</given-names></name><name><surname>Laifer</surname><given-names>G</given-names></name><name><surname>Goy</surname><given-names>G</given-names></name><etal/></person-group><article-title xml:lang="en">Endocarditis caused by <italic>Finegoldia magna</italic> (formerly Peptostreptococcus magnus): diagnosis depends on the blood culture system used</article-title><source>Diagn Microbiol Infect Dis</source><year>2003</year><volume>47</volume><fpage>359</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/S0732-8893(03)00091-9</pub-id></mixed-citation></ref></ref-list></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term>AHA</term><def><p id="Par5">American Heart Association</p></def></def-item><def-item><term>AV</term><def><p id="Par6">aortic valve</p></def></def-item><def-item><term>CRP</term><def><p id="Par7">C-reactive protein</p></def></def-item><def-item><term>CT</term><def><p id="Par8">computed tomography</p></def></def-item><def-item><term>ESC</term><def><p id="Par9">European Society of Cardiology</p></def></def-item><def-item><term>GPAC</term><def><p id="Par10">Gram-positive anaerobic cocci</p></def></def-item><def-item><term>IV</term><def><p id="Par11">intravenous</p></def></def-item><def-item><term>MIC</term><def><p id="Par12">minimum inhibitory concentration</p></def></def-item><def-item><term>MV</term><def><p id="Par13">mitral valve</p></def></def-item><def-item><term>POET trial</term><def><p id="Par14">Partial Oral Treatment of EndocarditisÂ trial</p></def></def-item></def-list></glossary><notes notes-type="Misc"><title>Publisherâs Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Cardiac Surgery</facet-value><facet-value count="1">Medicine &amp; Public Health</facet-value><facet-value count="1">Thoracic Surgery</facet-value></facet><facet name="keyword"><facet-value count="1">
                Finegoldia magna
              </facet-value><facet-value count="1">Administration</facet-value><facet-value count="1">Cardiac surgical procedures</facet-value><facet-value count="1">Infective endocarditis</facet-value><facet-value count="1">Oral antibiotics</facet-value><facet-value count="1">Prosthetic valve endocarditis</facet-value><facet-value count="1">Treatment outcome</facet-value></facet><facet name="pub"><facet-value count="1">Journal of Cardiothoracic Surgery</facet-value></facet><facet name="year"><facet-value count="1">2019</facet-value></facet><facet name="country"><facet-value count="1">India</facet-value><facet-value count="1">United Kingdom</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
